<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01047241</url>
  </required_header>
  <id_info>
    <org_study_id>201010</org_study_id>
    <secondary_id>2009-013801-33</secondary_id>
    <nct_id>NCT01047241</nct_id>
  </id_info>
  <brief_title>Nasal Administration of Sufentanil+Ketamine for Procedure-related Pain in Children</brief_title>
  <official_title>Nasal Administration of Sufentanil+Ketamine for Procedure-related Pain in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danish University of Pharmaceutical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Danish University of Pharmaceutical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to investigate the absorption and clinical effect of nasal
      administration of an analgesic nasal spray containing sufentanil+ketamine for pain related to
      medical procedures in hospitalized children.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The management of procedural pain in children ranges from physical restraint to
      pharmacological interventions. Pediatric formulations that permit accurate dosing, are
      accepted by children and a have a rapid onset of analgesia are lacking. The objectives were
      to investigate a pediatric formulation of intranasal sufentanil 0.5 mcg/kg and ketamine 0.5
      mg/kg for procedural pain and to characterize the pharmacokinetic (PK) profile. Fifty
      children (â‰¥10 kg) scheduled for a painful procedure were included in this prospective
      nonrandomized open-label clinical trial. Thirteen of these children had central venous access
      for drug assay sampling; enabling a compartmental PK analysis using nonlinear mixed-effects
      models. Pain intensity before and during the procedure was measured using age-appropriate
      pain scales. Heart rate, oxygen saturation and sedation were recorded.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Procedural Pain Intensity Score</measure>
    <time_frame>Pain assessment during painful medical procedure</time_frame>
    <description>Children &lt;5 years old were administered the FLACC (Face Leg Activity Cry Consolability) Scale (Range: 0-10, where 0 is no pain and 10 is worst pain). Children &gt;= 5 years but &lt; 8 years old were administered the Visual analog scale modified with six faces by Wong-Baker (Wong-Baker Faces Pain Rating Scale) (Range: 0-10, where 0 is no pain and 10 is worst pain). Children &gt;= 8 years old were administered a Visual Analog Scale (Range: 0-10, where 0 is no pain and 10 is worst pain).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of Sufentanil and Ketamine</measure>
    <time_frame>Time= 5-60 min after administration of the investigational medical product</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Bioavailability of Sufentanil and Ketamine</measure>
    <time_frame>Time= 5-60 min after administration of the investigational medical product</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Plasma Concentrations (Tmax) Sufentanil and Ketamine</measure>
    <time_frame>Time=5-60 min after administration of investigational medicinal product</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sedation Score (UMSS)</measure>
    <time_frame>Time= 0-70 min. after drug administration</time_frame>
    <description>University of Michigan Sedation Score (UMSS) (0-4, 0 &quot;awake and alert&quot;, 4 &quot;unarousable&quot;)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acceptance of Intranasal Administration</measure>
    <time_frame>Immediately after the procedure</time_frame>
    <description>Asking the children (parents for preverbal children) if they would like to receive this treatment again in a similar situation rather than analgesic suppositories, tablets, oral solutions, or injections?</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Intranasal sufentanil/ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intranasal combination of sufentanil and ketamine. Dose of sufentanil 0.5 mcg/kg and ketamine 0.5 mg/kg, single dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intranasal sufentanil/ketamine</intervention_name>
    <description>Nasal spray sufentanil+ketamine, 0,5 microg/kg sufentanil+0,5 mg/kg ketamine, single dose</description>
    <arm_group_label>Intranasal sufentanil/ketamine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children and adolescents treated at the University Hospital, Rigshospital

          -  Painful medical procedure related to the patients treatment

          -  Patient and/or the parents must be able to understand and speak danish

          -  Negative pregnancy test for girls, when relevant

          -  Signed informed consent

          -  Only a light meals or no meals have been ingested 2 hours prior to inclusion

        Exclusion Criteria:

          -  Allergy to sufentanil or ketamine

          -  Abnormal nasal cavity

          -  Have been treated with sufentanil and/or ketamine during the last 48 hours

          -  Nasal obstruction (rhinitis)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>19 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steen W Henneberg, MD DMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kjeld Schmiegelow, MD DMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Copenhagen University Hospital Righospitalet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Copenhagen University Hospital Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2010</study_first_submitted>
  <study_first_submitted_qc>January 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2010</study_first_posted>
  <results_first_submitted>January 6, 2014</results_first_submitted>
  <results_first_submitted_qc>September 12, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 17, 2014</results_first_posted>
  <last_update_submitted>September 12, 2014</last_update_submitted>
  <last_update_submitted_qc>September 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Danish University of Pharmaceutical Sciences</investigator_affiliation>
    <investigator_full_name>Bettina Nygaard Nielsen</investigator_full_name>
    <investigator_title>M.Sc. Pharm. sponsor contact person</investigator_title>
  </responsible_party>
  <keyword>Painful medical procedures</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Sufentanil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Intranasal Sufentanil+Ketamine</title>
          <description>Sufentanil, ketamine: Nasal spray sufentanil+ketamine, single dose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intranasal Sufentanil+Ketamine</title>
          <description>Sufentanil, ketamine: Nasal spray sufentanil+ketamine, single dose</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.8" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.9" spread="20.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="138.4" spread="32.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Preprocedural pain intensity</title>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Procedural Pain Intensity Score</title>
        <description>Children &lt;5 years old were administered the FLACC (Face Leg Activity Cry Consolability) Scale (Range: 0-10, where 0 is no pain and 10 is worst pain). Children &gt;= 5 years but &lt; 8 years old were administered the Visual analog scale modified with six faces by Wong-Baker (Wong-Baker Faces Pain Rating Scale) (Range: 0-10, where 0 is no pain and 10 is worst pain). Children &gt;= 8 years old were administered a Visual Analog Scale (Range: 0-10, where 0 is no pain and 10 is worst pain).</description>
        <time_frame>Pain assessment during painful medical procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intranasal Sufentanil/Ketamine</title>
            <description>Sufentanil/ketamine: Nasal spray containing a combination of sufentanil and ketamine. Dose sufentanil 0.5 micg/kg and ketamine 0.5 mg/kg, single dose</description>
          </group>
        </group_list>
        <measure>
          <title>Procedural Pain Intensity Score</title>
          <description>Children &lt;5 years old were administered the FLACC (Face Leg Activity Cry Consolability) Scale (Range: 0-10, where 0 is no pain and 10 is worst pain). Children &gt;= 5 years but &lt; 8 years old were administered the Visual analog scale modified with six faces by Wong-Baker (Wong-Baker Faces Pain Rating Scale) (Range: 0-10, where 0 is no pain and 10 is worst pain). Children &gt;= 8 years old were administered a Visual Analog Scale (Range: 0-10, where 0 is no pain and 10 is worst pain).</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" lower_limit="2.0" upper_limit="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Plasma Concentration (Cmax) of Sufentanil and Ketamine</title>
        <time_frame>Time= 5-60 min after administration of the investigational medical product</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intranasal Sufentanil/Ketamine</title>
            <description>Sufentanil/ketamine: Nasal spray containing a combination of sufentanil and ketamine. Dose sufentanil 0.5 micg/kg and ketamine 0.5 mg/kg, single dose Pharmacokinetic analysis: 13 children enrolled</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) of Sufentanil and Ketamine</title>
          <units>mcg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax sufentanil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.042" spread="0.005" lower_limit="0.151" upper_limit="0.277"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax ketamine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sedation Score (UMSS)</title>
        <description>University of Michigan Sedation Score (UMSS) (0-4, 0 &quot;awake and alert&quot;, 4 &quot;unarousable&quot;)</description>
        <time_frame>Time= 0-70 min. after drug administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intranasal Sufentanil/Ketamine</title>
            <description>Sufentanil/ketamine: Nasal spray containing sufentanil/ketamine. Dose sufentanil 0.5 mcg/kg and ketamine 0.5 mg/kg, single dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Sedation Score (UMSS)</title>
          <description>University of Michigan Sedation Score (UMSS) (0-4, 0 &quot;awake and alert&quot;, 4 &quot;unarousable&quot;)</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acceptance of Intranasal Administration</title>
        <description>Asking the children (parents for preverbal children) if they would like to receive this treatment again in a similar situation rather than analgesic suppositories, tablets, oral solutions, or injections?</description>
        <time_frame>Immediately after the procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intranasal Sufentanil/Ketamine</title>
            <description>Sufentanil/ketamine: Nasal spray containing a combination of sufentanil and ketamine. Dose sufentanil 0.5 mcg/kg and ketamine 0.5 mg/kg, single dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Acceptance of Intranasal Administration</title>
          <description>Asking the children (parents for preverbal children) if they would like to receive this treatment again in a similar situation rather than analgesic suppositories, tablets, oral solutions, or injections?</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Bioavailability of Sufentanil and Ketamine</title>
        <time_frame>Time= 5-60 min after administration of the investigational medical product</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intranasal Sufentanil/Ketamine</title>
            <description>Sufentanil/ketamine: Nasal spray containing a combination of sufentanil and ketamine. Dose sufentanil 0.5 micg/kg and ketamine 0.5 mg/kg, single dose Pharmacokinetic analysis: 13 children enrolled</description>
          </group>
        </group_list>
        <measure>
          <title>Bioavailability of Sufentanil and Ketamine</title>
          <units>percentage bioavailable</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bioavailability sufentanil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.6" spread="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bioavailability ketamine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.8" spread="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Maximum Plasma Concentrations (Tmax) Sufentanil and Ketamine</title>
        <time_frame>Time=5-60 min after administration of investigational medicinal product</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intranasal Sufentanil/Ketamine</title>
            <description>Sufentanil/ketamine: Nasal spray containing a combination of sufentanil and ketamine. Dose sufentanil 0.5 micg/kg and ketamine 0.5 mg/kg, single dose Pharmacokinetic analysis: 13 children enrolled</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Plasma Concentrations (Tmax) Sufentanil and Ketamine</title>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tmax sufentanil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tmax ketamine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Intranasal Sufentanil+Ketamine</title>
          <description>Sufentanil, ketamine: Nasal spray sufentanil+ketamine, single dose</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sponsor's contact person Bettina Nygaard Nielsen</name_or_title>
      <organization>Copenhagen University Hospital, Rigshospitalet</organization>
      <phone>+45 35459546</phone>
      <email>bettina.nygaard.nielsen@regionh.dk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

